drugset / Trial / NCT02093962

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

NCT02093962

Phase 2 Terminated 265 enrolled ImmunoGenesis EMD Serono · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.

Timeline

Start
2014-06
Primary completion
2016-04
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Evofosfamide Other / unclassified 400 mg/m2 Intravenous
Comparator Pemetrexed Small molecule 500 mg/m2 Intravenous